secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001323885-25-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q1 revenue $123.6M (+13.6% YoY); net loss improves to $6.7M from $13.2M
--------------------------------------------------------------------------------

- Revenue $123.6M (+13.6% YoY; +14.1% constant currency); U.S. $101.1M (+12.1%), International $22.5M (+20.8%).
- Net loss $6.7M ($0.14 per share) improved from $13.2M ($0.28 per share) a year ago.
- Adjusted EBITDA $8.8M, up from $2.8M in Q1 2024; gross margin 74.9% (+27 bps).
- Growth driven by EnCompass clamp, cryoSPHERE MAX probes, AtriClip Flex-Mini device launches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388525000041/0001323885-25-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388525000041/atrc-20250429.htm
  HTML page:      https://secwatch.observer/filing/0001323885-25-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer